• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    4/5/24 4:31:09 PM ET
    $ADIL
    $ATNF
    $CERS
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADIL alert in real time by email

    Gainers

    • Longeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million.
    • Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by 11.96% to $1.31. The market value of their outstanding shares is at $2.1 million.
    • Etao International Co (NASDAQ:ETAO) stock moved upwards by 11.11% to $2.7. The market value of their outstanding shares is at $13.8 million.
    • 180 Life Sciences (NASDAQ:ATNF) shares rose 7.35% to $2.39. The market value of their outstanding shares is at $1.7 million.
    • Inovio Pharmaceuticals (NASDAQ:INO) stock rose 6.99% to $12.62. The market value of their outstanding shares is at $294.9 million.
    • Gossamer Bio (NASDAQ:GOSS) stock increased by 6.79% to $1.1. The market value of their outstanding shares is at $248.1 million.

    Losers

    • Elicio Therapeutics (NASDAQ:ELTX) stock declined by 10.3% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $81.1 million.
    • SINTX Techs (NASDAQ:SINT) shares decreased by 4.9% to $0.02. The market value of their outstanding shares is at $1.1 million.
    • Cerus (NASDAQ:CERS) stock fell 4.82% to $1.78. The market value of their outstanding shares is at $322.6 million.
    • MediciNova (NASDAQ:MNOV) shares declined by 4.7% to $1.42. The company's market cap stands at $69.6 million.
    • Vor Biopharma (NASDAQ:VOR) stock fell 4.63% to $2.06. The market value of their outstanding shares is at $140.4 million.
    • Stoke Therapeutics (NASDAQ:STOK) stock declined by 4.33% to $12.03. The market value of their outstanding shares is at $623.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $ATNF
    $CERS
    $ELTX

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    3/23/2026Overweight → Neutral
    Cantor Fitzgerald
    Vor Biopharma Inc.
    $VOR
    3/19/2026$30.00Overweight
    Wells Fargo
    Medicinova Inc
    $MNOV
    3/16/2026$10.00Buy
    H.C. Wainwright
    Elicio Therapeutics Inc.
    $ELTX
    3/10/2026$17.00Buy
    Rodman & Renshaw
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    Stoke Therapeutics Inc.
    $STOK
    2/24/2026$40.00Outperform
    Wolfe Research
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $ADIL
    $ATNF
    $CERS
    $ELTX
    SEC Filings

    View All

    SEC Form 8-K filed by Stoke Therapeutics Inc.

    8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)

    3/27/26 4:30:26 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.

    SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    3/27/26 1:18:27 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Gossamer Bio Inc.

    SCHEDULE 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    3/27/26 9:31:28 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ATNF
    $CERS
    $ELTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vor Bio Announces $75 Million Private Placement with TCGX

    BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $75 million, before deducting any offering-related expenses. Vor Bio did not engage a placement agent in connection with the private placement. The private placement is expected to close on or about March 30, 2026, subject to the satisfaction of customary closing conditions. The fin

    3/27/26 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans

    GLEN ALLEN, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today commended members of the U.S. Congress for introducing H.R. 7091, the Expanding Veterans' Access to Emerging Treatments Act, bipartisan legislation aimed at expanding research and development of emerging therapies for conditions affecting U.S. veterans, specifically including Alcohol Use Disorder (AUD). Alcohol Use Disorder remains a significant issue within the veteran population, with nearly 40% of veterans experiencing AUD at some point in t

    3/24/26 9:07:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 215,700 shares of Vor Bio's common stock and restricted stock units ("RSUs") representing the right to receive an aggregate of 46,235 shares of Vor Bio's common stock to 8 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor B

    3/23/26 4:30:00 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $ATNF
    $CERS
    $ELTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Allan Jonathan

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    3/24/26 4:19:20 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Aranda Richard

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    3/20/26 4:22:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Peterson Caryn

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    3/20/26 4:20:55 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ATNF
    $CERS
    $ELTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ADIL
    $ATNF
    $CERS
    $ELTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Gossamer Bio from Overweight to Neutral

    3/23/26 8:26:50 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Vor Biopharma with a new price target

    Wells Fargo initiated coverage of Vor Biopharma with a rating of Overweight and set a new price target of $30.00

    3/19/26 8:27:43 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on MediciNova with a new price target

    H.C. Wainwright initiated coverage of MediciNova with a rating of Buy and set a new price target of $10.00

    3/16/26 8:42:01 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ATNF
    $CERS
    $ELTX
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

    William "Obi" Greenman to become Executive Chairman Leadership changes to take effect July 1, 2026 Cerus Corporation (NASDAQ:CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be promoted to president and chief executive officer, effective July 1, 2026. William "Obi" Greenman will become executive chairman of the board of directors. At the time of his appointment, Mr. Jayaraman will join the Board of Directors. "Following a thorough succession planning process, this transition represents a natural step as we prepare for the next phase of growth at Cerus," said Frank Witney, lead independent director on the Cerus Board of Directors. "The Board and I are de

    3/16/26 4:05:00 PM ET
    $CERS
    EDP Services
    Technology

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ADIL
    $ATNF
    $CERS
    $ELTX
    Financials

    Live finance-specific insights

    View All

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

    - Following PROSERA Phase 3 topline results, the Company is focused on evaluating the totality of the dataset, engaging with the FDA, and assessing strategic options and capital allocation - - Enrollment in the Phase 3 SERANATA Study in PH-ILD has been paused while the Company evaluates implications of PROSERA results - - The Company implemented a reduction in force to align resources with near-term priorities - - Cash, cash equivalents and marketable securities totaled $137 million at year-end 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH)

    3/17/26 4:01:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U.S. Food and Drug Administration (FDA); target Prescription Drug User Fee Act (PDUFA) date October 30, 2026 INO-3107 immunological and long-term clinical and safety data published in Nature Communications and The Laryngoscope Advanced promising next-generation DNA medicine technology:Phase 1 proof-of-concept trial of DNA-encoded Monoclonal Antibodies (DMAbs) published in Nature MedicinePromising preclinical data on novel DNA-encoded protein (DPROT) technology presented at the World Federation of

    3/12/26 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $ADIL
    $ATNF
    $CERS
    $ELTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vor Biopharma Inc.

    SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

    11/14/24 4:33:50 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $ATNF
    $CERS
    $ELTX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care